Kornimate/medical-research-clean huggingface dataset:
impact of front-of-package warning labels on perceived weight stigmatization

Conditions: Weight Stigma

Summary: the goal of this experiment is to examine the effects of three different types of front-of-package warning labels for sugar-sweetened beverages on perceived weight stigmatization, as well as the effect of making such labels more weight-neutral. the main questions this experiment aims to answer are: * are certain types of front-of-package warning labels perceived as more stigmatizing than others? * are more weight-neutral versions of front-of-package warning labels perceived as less stigmatizing than their regular versions? * is there a trade-off between label effectiveness in discouraging product consumption and perceived weight stigmatization? additionally, this experiment also aims to answer the following questions: * does exposure to certain types of front-of-package warning labels lead to changes in participants' weight bias? * are changes in participants' weight bias as a result of label exposure mediated by attribution of personal responsibility for body weight, pathogen disgust, or perceived social consensus?

participants will be randomly assigned to see one of four types of labels: control labels, nutrient warning labels, text-only health warning labels, or graphic health warning labels. participants will then see an image depicting different types of fictional sugar-sweetened beverages carrying the label type that they were assigned to. participants will see this image twice, in random order, each time differing in whether the label is weight-neutral or not (i.e., whether the label references calories/obesity or not). each time, participants will answer survey questions about the label. last, participants will answer survey questions measuring their weight bias and potential mediating variables.

Eligibility criteria:
inclusion criteria: * at least 21 years of age. * residing in the us. exclusion criteria: -involved in any pre-testing.
couples' qol in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the primary objectives of this study are to adapt and evaluate a sexual quality of life intervention in women with metastatic breast cancer and their partners.


Eligibility criteria:
inclusion criteria: * patient is female * patient is at least 18 years old * patient has a diagnosis of metastatic (stage iv) breast cancer * patient has a partner or spouse who is at least 18 years old * patient lives with a romantic partner (same or opposite sex) for at least 6 months * patient scores 3 or above on patient care monitor sexual concerns item (range: 0-10) exclusion criteria: * patient or partner is not able to speak and read english * patient or partner has a hearing impairment * patient or partner medically unable to participate as judged by physician/in medical record or by self-report * patient and partner do not have reliable telephone access * patient has overt cognitive dysfunction or psychiatric disturbance such as suicidal ideation or severe mental illness, as observed or judged by the researcher, physician or referring source, or self-report * patient past or current history of any cancer other than non-melanoma skin cancer or breast cancer * patient is currently participating in couple/marital therapy * patient is currently pregnant
a trial of trametinib and panitumumab in ras/raf wild type advanced colorectal cancer

Conditions: Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype

Summary: this is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful the combination of two drugs, panitumumab and trametinib, are in patients with advanced colorectal cancer with kras, nras, or braf wild type (genes that are not mutated). panitumumab is a drug that is approved by health canada for the treatment of advanced colorectal cancer with kras wild type. panitumumab works by binding to and blocking the protein, epidermal growth factor receptor (egfr) from working. trametinib is a drug that is approved by health canada for the treatment of melanoma with a mutation in the braf gene. trametinib works by binding to and blocking mitogen-activated protein kinase kinase (mek) 1 and mek2 from working. previous studies have shown that the combination of panitumumab and trametinib may be more useful in kras, nras, or braf wild type colorectal cancer.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * kras/nras/braf wild type colorectal cancer, not responsive to standard therapies, no approved or curative therapy, refuse standard therapy * prior 5-fu, oxaliplatin and irinotecan * ecog performance status of 0 or 1 * able to swallow/retain oral drugs * able and agree to have provide tumor tissue/have biopsies * agree to use contraception * not pregnant * adequate organ system function exclusion criteria: * chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapies \<28 days or 5 half lives * prior egfr, mek, or raf inhibitor or regorafenib * current use of prohibited medications * unresolved side effects * gi disease or other condition affecting gi absorption * mucosal or internal bleeding * any major surgery \<four weeks * hiv, hbv, or hcv positive * active infection * leptomeningeal disease * brain metastases * unacceptable qtcf interval * significant uncontrolled arrhythmias * acute coronary syndromes, myocardial infarction, coronary angioplasty, or stenting or bypass grafting \< 6 mos. * class ii, iii, or iv heart failure * other clinically significant ecgs * intra - cardiac defibrillators * cardiac metastases * condition that may interfere with patient safety * hypersensitivity to study drugs * severe or uncontrolled systemic diseases * pregnant or lactating * retinal vein occlusion * interstitial lung disease or pneumonitis * active liver or biliary disease
vitamin d3 levels in covid-19 outpatients from western mexico

Conditions: Covid19

Summary: the immunomodulatory effects of vitamin d are known to be beneficial in viral infections, it is also known that its deficiency is associated with a worse prognosis of covid-19. this study aimed to determine the baseline vitamin d serum concentrations in asymptomatic or mildly symptomatic covid-19 outpatients, as well as to evaluate the effects of supplementation with 10,00 iu/daily of vitamin d3 and its relationship with biochemical parameters and clinical features.


Eligibility criteria:
inclusion criteria: * intervention group: patients with positive pcr for covid-19 of both sexes supplemented with vitamin d * control group: patients with positive pcr for covid-19 of both sexes * both groups: mexican individuals, after signing the informed consent letter and over 18 years of age. exclusion criteria: • diseases that compromise the absorption of vitamin d; crohn's disease, cystic fibrosis, and celiac disease.

Keywords: vitamin d latin america supplementation
efficacy of laser versus cryotherapy in the treatment of warts

Conditions: Warts

Summary: the purpose of this study is to test the efficacy of laser versus cryotherapy on the treatment of warts

cutaneous warts were a common skin diseases caused by human papilloma virus (hpv) infection. although warts may spontaneously resolve, many patients seek for treatment for various reasons. there are many kinds of treatments for cutaneous warts, including salicylic acid, cryotherapy, laser, etc. a recent high quality rct confirmed that the cure rate of topical salicylic acid and frozen has no difference at six months, but the efficacy of laser versus cryotherapy on the treatment of warts remains unclear. therefore, we designed a randomized controlled trial to test the efficacy of laser versus cryotherapy on the treatment of warts.

Eligibility criteria:
inclusion criteria: * patients have cutaneous warts, including common warts(d≥1cm or n≥5 ), plantar warts, periungual warts, mosaic warts, which are suitable for cryotherapy and laser treatment . * patients aged eighting years and over, who have junior school degree or above exclusion criteria: * patients who have more than 20 warts * patients who are currently participating in another trial for the treatment of their warts * patients who took immunosuppressant drugs such as oral corticosteroids within the past three months. * patients who are pregnant or ready for pregnancies or breast-feeding. * patients who have impaired healing eg due to diabetes, vascular disease, vitamin a deficiency, hyperthyroidism and hypothyroidism. * patients who have autoimmune diseases, eg sle, dermatomyositis, scleroderma and other diseases . * patients who have cold intolerance, eg cold urticaria, cryoglobulinaemia, cold agglutinin syndrome, raynaud's syndrome. * patients who have local injections intolerance. * patients who have local hypoesthesia . * patients who can not tolerate cryotherapy or laser treatment for their own reasons.

Keywords: cryotherapy laser cutaneous warts
a safety study of sgn-liv1a in breast cancer patients

Conditions: HER2 Positive Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Triple Negative Breast Neoplasms; HER2 Mutations Breast Neoplasms

Summary: this study will examine the safety and tolerability of ladiratuzumab vedotin (lv) in patients with metastatic breast cancer. lv will be given alone or in combination with trastuzumab.


Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of breast cancer with radiographic evidence of incurable, unresectable, locally advanced or metastatic disease (la/mbc) * one of the following: * part a: triple-negative disease (er/pr/her2-negative) and received at least 2 prior cytotoxic regimens in the incurable, unresectable, la/mbc setting; or er-positive and/or pr-positive/her2-negative disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, la/mbc setting and are no longer a candidate for hormonal therapy (not enrolling new patients); * part b: combination arm: her2-positive disease and received at least 2 prior cytotoxic regimens in the incurable, unresectable, la/mbc setting (not enrolling new patients); * part c: triple-negative disease and received 2-4 prior non-hormonally-directed therapies in the mbc setting (not enrolling new patients); * part d and part e (dose-expansion cohort): triple-negative disease and received 1 prior non-hormonally-directed or cytotoxic therapy in the mbc setting; or * part e: hr+(er-positive and/or pr-positive)/her2-negative disease who are chemotherapy-eligible and not considered a candidate for further hormonal therapy. must have received no more than 1 prior non-hormonally-directed or cytotoxic therapy in the la/mbc setting. * part f: all of the following: * triple negative breast cancer * no prior cytotoxic chemotherapy for unresectable locally advanced or metastatic stage disease * tumor tissue pd-l1 expression cps \<10 expression * parts a, b, c, and d: newly obtained or archived tumor tissue biopsy, must be collected for central pathology determination of liv-1 expression * parts e and f: archival or fresh baseline tumor sample is required. * measurable disease * eastern cooperative oncology group performance status 0 or 1 * combination arm: adequate heart function exclusion criteria: * pre-existing neuropathy grade 2 or higher * parts a, b, c, and d: cerebral/meningeal disease that is related to the underlying malignancy and has not been definitively treated. parts e and f: known or suspected cerebral/meningeal metastasis that has not been definitively treated. * prior treatment with lv or prior treatment with an mmae-containing therapy * combination arm: hypersensitivity to trastuzumab

Keywords: monomethyl auristatin e antibody-drug conjugate drug therapy metastatic liv-1 protein, human trastuzumab ladiratuzumab vedotin hliv22-vcmmae seattle genetics
a study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy (sma)

Conditions: Muscular Atrophy, Spinal

Summary: the purpose of this open-label, single arm study is to further evaluate long-term tolerability, safety and efficacy outcomes of olesoxime in participants with spinal muscular atrophy (sma) who previously participated in one of the following two clinical studies: tro19622 cl e q 1115-1 (open-label phase ib, multicenter, single- and multiple- dose study) or tro19622 cl e q 1275-1 (nct01302600, phase ii/iii, adaptive, parallel-group, double blind, randomized, placebo-controlled, multicenter, multinational study).


Eligibility criteria:
inclusion criteria: * participation in the previous studies (tro19622 cl e q 1115-1 or tro19622 cl e q 1275-1) * for women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 28 days after the last dose of olesoxime exclusion criteria: * female participants who are pregnant or lactating, or intending to become pregnant during the study * participants who, in the opinion of the investigator, are not suitable to participate in this open-label study * participants who have developed study drug hypersensitivity to olesoxime or one of the formulation excipients, including sesame oil * concomitant or previous participation in any investigational drug or device study within 90 days prior to screening * concomitant or previous participation in a survival motor neuron 2 (smn2) targeting antisense oligonucleotide study within 6 months prior to screening * history of human immunodeficiency virus infection, history of hepatitis b infection within the past year, history of hepatitis c infection which has not been adequately treated * history of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment * any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study * history or presence of an abnormal electrocardiogram (ecg) that is clinically significant in the investigator's opinion
effectiveness of photo-biomodulation in the treatment of chemotherapy induced mucositis

Conditions: Mucositis

Summary: the aim of the current study was to study the effect of diode laser in the treatment of chemotherapy induced mucositis in young patients suffering from leukemia


Eligibility criteria:
inclusion criteria: * children diagnosed with mucositis and receiving chemotherapy exclusion criteria: * diabetes * trismus

Keywords: mucositis - leukemia - chemotherapy
the effect of a smartphone-assisted hybrid cardiac rehabilitation program in patients with heart failure.

Conditions: Heart Failure

Summary: the aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with hf. participants will undergo a 12-week program led by a case manager and assisted by a smartphone. the study aims to answer two main questions: 1. is the novel cardiac rehabilitation model feasible for patients with hf? 2. does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?


Eligibility criteria:
inclusion criteria: * patients with heart failure between the ages of 18 and 80 years old. * nyha (new york heart association) functional classification of 1 to 3. * patients must be in a stable condition and under outpatient follow-up. exclusion criteria: * patients who have contraindications for exercise according to the american college of sports medicine's guidelines for exercise testing and prescription. * patients who are unable to complete cardiopulmonary exercise testing. * patients who are unable to follow verbal instructions. * patients who are unable to walk independently or pedal a stationary bicycle. * patients who are unable to use communication app on a smartphone. * patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation. * patients who do not provide consent to participate in the trial.

Keywords: cardiac rehabilitation heart failure ehealth
prehabilitation for adults with end stage renal disease on the kidney transplant waitlist

Conditions: Kidney Failure, Chronic

Summary: this pilot study will be a clinical trial to test the feasibility and effectiveness of a kidney transplant (kt) prehabilitation intervention in adults with end stage renal disease (esrd) who are within 3-6 months of transplantation.

prehabilitation is the enhancement of functional capacity of a patient to improve their ability to withstand a future stressor. the investigators primary objective is to demonstrate feasibility for prehabilitation in aim 1 and test whether the number of prehabilitation sessions is associated with increased physical activity. the investigators will formally test whether prehabilitation is associated with a reduction in short term and long term kt outcomes as part of aim 2. the investigators will test whether there is an effect of prehabilitation on short-term (kt length of stay\> 2 weeks, early hospital readmission and delayed graft function) and long-term (acute rejection (within the first year), 1 year patient and graft survival) outcomes compared to standard of care controls. participants will be followed for 3-6 months or until they receive a kidney transplant.

Eligibility criteria:
inclusion criteria: 1. men and women with end stage renal disease who are within 3-6 months of kidney transplantation and are on the kidney transplant waitlist at johns hopkins 2. must be at least 18 years or older at enrollment 3. must be english speaking 4. must be enrolled in an ongoing cohort study of adults with esrd who are being evaluated for kidney transplantation 5. must be willing to participate in a prehabilitation program and able to give informed consent exclusion criteria: 1. patients who have any of the following medical conditions will be excluded from the study: * active angina pectoris * chronic lung disease and daily use of oxygen * cerebral vascular disease * musculoskeletal conditions that would limit participation in prehabilitation * lower- or upper-extremity amputation * orthopedic disorders exacerbated by physical activity * decreased mental capacity 2. patients who live outside of maryland will not be included in the study.
evaluation of the intra-observer agreement of the hep score in surgical intensive care.

Conditions: Heparin-induced Thrombocytopenia

Summary: the main objective of this work is to assess the intraoperator reproducibility in the calculation of the hep score in a population of intensive care patients.

the "hep score" (hit expert probability) is also a clinical probability score, created thanks to the experience of clinicians (16). it is very recent and therefore still little studied and little used. in particular, it has not been the subject of a prospective validation study for icu patients. the use of this score is therefore not recommended in everyday practice. however, the literature shows a higher diagnostic value of the hep score especially for resuscitation-type patients, as well as when used by an operator with little experience. this could be due to greater detail given in consideration of other causes of thrombocytopenia (17). the main objective of this work is to assess the intraoperator reproducibility in the calculation of the hep score in a population of intensive care patients. the secondary objectives will aim to: * evaluate inter-operator reproducibility * determine if the reproducibility of the hep score is influenced by: the patient's sex the type of heparin used (lmwh vs ufh) the severity of the patient (igs2 score) a history of cardiac or orthopedic surgery the expected consistent benefits allow validation of the hep score in surgical intensive care (cf. evhep-tih study). this would allow a better assessment of the pre-test probabilities of tih with the performance of biological tests.

Eligibility criteria:
inclusion criteria: * any adult patient (age ≥ 18 years), admitted to surgical intensive care, treated with heparin (ufh or lmwh), and suspected of tih by a clinician in the department according to the criteria of the sfar 2002. exclusion criteria: * non-inclusion criteria: minor patients, pregnant women and adults incapable

Keywords: heparin-induced thrombocytopenia hep score
study of subcutaneous campath-1h in patients with b-cell cll and residual disease after chemotherapy

Conditions: B-Cell Chronic Lymphocytic Leukemia

Summary: to evaluate whether campath-1h given to patients with cll after maximum response to chemotherapy will: a) eliminate minimal residual disease (documented by flow cytometry) in patients who have achieved a complete remission (cr) or b) convert partial remission to complete remission. to evaluate the time-to-progression of patients according to pretreatment characteristics and response status at study entry. to evaluate whether campath-1h given to patients with cll after maximum response to chemotherapy will eliminate minimal residual disease as determined by real-time quantitative pcr.

approximately 95% of cases involve the clonal proliferation of b cells. paraproteins, often of the igm class, can be detected in the serum and/or urine of most patients with cll. unique cell surface markers are increasingly being used to diagnose the disease, and in approximately 40% of patients, cytogenetic abnormalities (for example, trisomy 12) can be found. patients commonly present with lymphocytosis, lymphadenopathy, splenomegaly and symptoms of fatigue, weight loss, and malaise. in more advanced cases anemia and thrombocytopenia can also occur. the clinical course of cll is unpredictable, with survival from initial diagnosis varying from 1 to 20 years (2). in addition, there is a subset of patients with indolent cll whose absolute lymphocyte count is less than 30 x 109/l and who rarely die from the disease. cll is commonly staged according to the 5-point system proposed by rai (appendix b) and co-workers. while rai staging is a relatively good predictor of overall survival, it cannot predict the prognosis in individual patients.

Eligibility criteria:
inclusion criteria: * male or female, at least 18 years old. * signed informed consent. * zubrod performance status of 0, 1, or 2 (appendix c). * patients with cll, cll/pll or pll (prolymphocytic) who have achieved a clinical complete remission by nci-wg criteria with chemotherapy, eg., alkylating agents, fludarabine or chemoimmunotherapy but have documentation of residual disease by immunophenotyping showing: (a) a residual population of cd5 and cd19 positive cells that comprise ≥ 10% of the marrow mononuclear cell population; or (b) a residual population of cd5 and cd19 positive cells that comprise \ 6 or \<.33. * patients with cll who have achieved a partial remission (pr) or nodular partial remission (npr) by nci-wg criteria after chemotherapy. * creatinine, bilirubin, ast or alt and alkaline phosphatase ≤2 x the upper limit of normal. exclusion criteria: * active infection. * past history of anaphylaxis, following exposure to rat or mouse derived cdr-grafted humanized monoclonal antibodies. * less than 2 months since prior chemotherapy. * previous treatment with campath-1h. * pregnant or nursing women. * patients on corticosteroids. * uncontrolled autoimmune hemolytic anemia.

Keywords: leukemia chronic chronic lymphocytic leukemia campath alemtuzumab mabcampath subcutaneous cll c-cll residual